(Q51752412)

11 April 2018

http://europepmc.org/abstract/MED/24553387

title

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. (English)

1 reference

11 April 2018

http://europepmc.org/abstract/MED/24553387

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Federica Di Nicolantonio

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sabrina Arena

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Simona Lamba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Giulia Siravegna

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Mariangela Russo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Andrea Sartore-Bianchi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

A Amatu

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Emanuele Valtorta

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Salvatore Siena

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Alberto Bardelli

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

13

Calogero Lauricella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

6

Sebastijan Hobor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

8

Michela Buscarino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Alice Lallo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Luca Lazzari

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Katia Bencardino

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

1 February 2014

1 reference

11 April 2018

http://europepmc.org/abstract/MED/24553387

published in

Science Translational Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

224ra26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24553387%20AND%20SRC:MED&resulttype=core&format=json

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Epidermal growth factor receptor pathway mutations and colorectal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Targeted therapies: how personal should we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

MEK and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Liquid biopsy: monitoring cancer-genetics in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Detection of circulating tumor DNA in early- and late-stage human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Molecular origins of cancer: Molecular basis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

A systematic review of treatment guidelines for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Treatment of metastatic colon cancer: "the times they are A-changing".

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947

Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3007947